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Introduction {#sec005}
============

The Metabolic Syndrome (MetS) is a cluster of cardiovascular and metabolic risk factors including central obesity, hypertension, hyperglycemia and dyslipidemia. These well-known risk factors co-segregate in an individual more often than might be expected by chance, and predispose to type 2 diabetes mellitus and to cardiovascular disease (CVD). The etiology of MetS is not yet well understood, but predisposing factors include aging, inflammation, obesity, sedentary, lifestyle and genetics \[[@pone.0174945.ref001]\]. The insulin resistance is likely to be a significant link between the components of MetS. Increased oxidative stress and inflammation have emerged as playing a central role in MetS and may be a unifying factor in the progression of this disease. Central obesity is the principal component of the MetS that determinates the progression of those metabolic complications. However, a subgroup of obese individuals seems to be protected against obesity-related metabolic complications \[[@pone.0174945.ref002]\]. These individuals are described as metabolically healthy obese (MHO), or as having uncomplicated obesity \[[@pone.0174945.ref003]\]. It is a new concept in which an individual may exhibit an obese phenotype without the presence of MetS. The existence of MHO phenotype was first proposed by Sims in 2001; it is considered that a proportion between 15% and 20% of obese individuals may be free of metabolic complications during an unknown period of time \[[@pone.0174945.ref004]\]. The subjects with MHO do not exhibit at baseline an increased mortality, or an increased risk of CVD or type 2 diabetes compared to normal-weight controls \[[@pone.0174945.ref005]\].

Telomere length (TL), generally assessed in leukocytes, is a novel marker of cellular aging and has been associated with increased risks of morbidity and mortality \[[@pone.0174945.ref006],[@pone.0174945.ref007]\]. Telomeres are nucleoprotein complexes located at the ends of eukaryotic chromosomes, composed of DNA tandem repeats (TTAGGG in mammals) and associated proteins. They play an essential role in preserving chromosomal integrity and stability, constituting a critical factor in cell survival \[[@pone.0174945.ref008]\]. Telomeric DNA erodes with each cell division by incomplete replication of the lagging strand during DNA synthesis, known as the "end-replication problem". Through this process, each telomeric end shortens by approximately 20--60 base pairs (bp)/year in peripheral blood lymphocytes \[[@pone.0174945.ref009]--[@pone.0174945.ref011]\]. In vitro studies have found that when telomeres become critically short, cells stop dividing and promote replicative senescence, contributing to ageing and subsequent somatic cells death \[[@pone.0174945.ref012]\]. Cellular damage due to increased oxidative stress \[[@pone.0174945.ref013]\] can further accelerate the process of TL reduction. Therefore, TL can be considered as a biomarker of aging, where shorter TL would indicate increased biological age. Indeed, metabolic disorders such as MetS, which is aging related, display functional decline in tissues such as the heart, liver and pancreas that are well-recognized features in aged individuals \[[@pone.0174945.ref014],[@pone.0174945.ref015]\]. Some studies have shown significant associations between shorter TL and central adiposity \[[@pone.0174945.ref016]\]. In this way, the TL was shorter according to the worsening of the metabolic condition in a representative sample of females \[[@pone.0174945.ref017]\]. It is known that there is a complex relationship between TL with obesity and the MetS components, but we do not know the impact of the TL in particular groups of obesity such as MHO. In this context, the principal aim of this study was to investigate the absolute TL (aTL) in MHO individuals, who were compared with a control group composed of non-obese individuals without MetS and with a cohort of patients with obesity and MetS.

Material and methods {#sec006}
====================

Population {#sec007}
----------

From the general population of Venado Tuerto, Province of Santa Fe, 1098 adult individuals of both sexes were selected randomly in 2011 following a stratified multistage sampling design, in accordance to the latest population census performed in 2010. Of the total population, 637 individuals agreed to participate in the study, and we carried out this work only in women (n = 400) taking into account gender differences in aTL \[[@pone.0174945.ref018],[@pone.0174945.ref019]\]. The study was approved by the Ethics Committee of Venado Tuerto Hospital and all participants gave their written informed consent. The prevalence of chronic metabolic diseases and the study of biochemical markers associated with CVD in the population are already published \[[@pone.0174945.ref020]\]. MHO group was defined as individuals with obesity but without MetS \[[@pone.0174945.ref021]\]. For the diagnosis of obesity, body mass index (BMI) ≥ 30 kg / m^2^ was considered. The diagnosis of MetS was performed according to the ATPIII criteria \[[@pone.0174945.ref022]\], as individuals with three or more of the following components for women: waist circumference ≥ 88 cm; fasting plasma glucose (FPG) ≥ 100 mg dl-1 or individual treated for type 2 diabetes; systolic blood pressure (SBP) ≥ 130 mmHg / diastolic blood pressure (DBP) ≥ 85 mmHg or individual treated for hypertension; high-density lipoprotein cholesterol (HDL-C) \< 50 mg dl-1 and triglycerides (TG) ≥ 150 mg dl-1 or individual treated for dyslipidemia. For aTL study, MHO women were compared with two other groups: obese women with MetS (MSO), a group with worse metabolic condition, consisting of individuals with both MetS and obesity; and metabolically healthy non-obese women (MHNO), a group with better metabolic condition, composed of individuals without obesity and MetS. In addition, we regrouped our population based on the number of components of MetS, into groups of individuals without any component of MetS (0), with one component (1), two components (2) and MetS with three or more components.

As TL was reported to be associated with the level of physical activity \[[@pone.0174945.ref023]\] and the lifetime accumulated exposure to tobacco \[[@pone.0174945.ref024]\], all subjects completed a questionnaire detailing their self-reported physical activity and cigarette smoking habits. It was considered the physical activity level during leisure time and at work, and it was classified into 3 categories, where 1 indicates inactive; 2, light to moderate activity; and 3, heavy activity. To measure the exposure to tobacco, pack-years smoked were calculated as the number of packs (20 cigarettes) smoked per day multiplied by years of smoking.

Anthropometric measurements (height, weight and waist circumference), and SBP and DBP were determined by a standardized protocol. BMI was calculated as weight (kg) / \[height (m)\]^2^. After a 12 h overnight fast, venous blood samples (20 mL) were drawn in every individual. One aliquot of blood was frozen at -20°C and reserved for DNA extraction. The remaining aliquot was centrifuged to obtain serum and analyzed immediately. FPG was determined by a glucose-oxidase method (GLU Glucose GOD-PAP, Roche Diagnostics, Mannheim, Germany) in a Hitachi 727 auto-analyzer. Fasting serum insulin (FSI) was measured by electrochemiluminescence immunoassay with a commercial kit (Insulin, Roche Diagnostics, Mannheim, Germany) in a Cobas e411 (Roche Diagnostics, Mannheim, Germany), with a lower detection limit of 2 μU/mL. As an indicator of insulinresistance we used the homoeostasis model assessment (HOMA), calculated as FPG (mM) \* FSI (mIU/L) / 22.5. TG and HDL-C were determined in serum using standardized procedures by enzymatic methods using commercial kits (TG Triglycerides GPO-PAP, and Phosphotungstate Precipitant and CHOL Cholesterol CHOD-PAP, Roche Diagnostics, Mannheim, Germany) by using a Hitachi 727 auto-analyzer. Intra-CV (coefficient of variation) for TG and HDL-C were 1.3% and 1.1%, respectively. Inter-CVs were 2.4% and 1.5%, respectively. Serum high-sensitivity C reactive protein (hs-CRP) levels were measured using particle enhanced immunonephelometry assay (Cardio Phase® hsCRP, Siemens) on a Siemens BN Prospect Nephelometer (Siemens Healthcare Diagnostics, Deerfield, IL, USA). We considered that hs-CRP values \>10 mg/l were likely to represent an acute inflammatory response in line with previous studies \[[@pone.0174945.ref025]\].

Measurement of absolute TL {#sec008}
--------------------------

We carried out the aTL measurement by qPCR as previously described \[[@pone.0174945.ref026]\], in a LightCycler system (Roche Diagnostics, Mannheim, Germany), which was previously validated by our working group \[[@pone.0174945.ref027]\]. Genomic DNA was extracted from peripheral blood leucocytes. For each DNA sample, two consecutive reactions were performed: the first one to amplify a fragment of 75 bp of the single copy gene RPLPO (ribosomal protein, large, PO), and the second one for the telomeric sequence. Primers sequences for RPLPO PCR were `5’-CAGCAAGTGGGAAGGTGTAATCC-3'` (forward), and `5’-CCCATTCTATCATCAACGGGTACAA-3'` (reverse); and for the telomere PCR were `5’-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-3'` (forward), and `5’-GGCTTGCCTTACCCTTACCCTTACCCTTACCCAATCCCT-3'` (reverse). Both PCRs were performed in a final volume of 20 μl containing 20 ng DNA, 1X SYBR Green Master Mix (Roche Diagnostics, Mannheim, Germany) and 250 nM RPLPO primers or 100 nM telomere primers. The PCR conditions were: 10 min at 95°C, followed by 45 cycles of 15 sec at 95°C, 1 min at 60°C. The melting curve was performed with 1 cycle of 20 sec at 95°C, 15 sec 50°C, and 98°C with a temperature ramp of 0.1°C/sec. Each sample was analyzed in duplicate, and all measurements included the determination of the standards and a no-template negative control, in which the DNA was substituted by water. We run a standard curve in each PCR, constructed using ten-fold serial dilutions of synthesized oligonucleotides. For the RPLP0 PCR we used the RPLP0 PCR product as standard, and the export values from the standard curves were diploid genome copies/reaction. The standard for telomere PCR is an oligomer containing only the telomeric DNA tandem repeats (TTAGGG repeated 14 times), and the export values from the standard curves were kbp of telomeric sequences/reaction. The kbp/reaction value was divided by the diploid genome copy number/reaction to calculate the aTL in kbp per human diploid genome, and then divided by the 92 telomeres present in a human genome to inform the aTL in kbp per telomere. To evaluate the reliability of the assay we calculated the intra and inter-CV, and they were sufficiently low for the RPLPO PCR (0.6% and 3.9%, respectively) and for the telomere PCR (1.6% and 10.4%, respectively).

Statistical evaluation {#sec009}
----------------------

Statistical analyses were performed using SPSS version 20.0 (IBM Corp., Armonk, NY, USA). We used one way-ANOVA and Bonferroni *post-hoc* test to compare biochemical, clinical and anthropometric characteristics between groups. In agreement with the Central Limit Theorem, due to the number of included patients, these variables were treated as normally distributed. Linear regression was performed to evaluate the relationship between aTL and age for the general population. The analysis of aTL in the groups MHNO, MHO and MSO, was performed by multiple linear regression considering the groups as ordinal variable, since each group shows a worse metabolic condition than the previous one; and the study of dummy variables to compare the aTL between every pair of groups. In this analysis, the age-squared, pack-years smoked and physical activity were used as covariates, as they were associated with aTL. The same analysis was performed to evaluate the relationship between the aTL and the number of components of MetS. A p value below 0.05 was considered as statistically significant.

Results {#sec010}
=======

The overall population consisted of 400 women with a mean age of 46.76 years (SD = 15.47; range: 18--86 years). Taking into account biochemical, clinical and anthropometric measurements, we observed that 49.0% of the cohort (n = 196) were MHNO, 10.5% (n = 42) MHO and 25.5% (n = 102) MSO. The remaining 15.0% of the cohort (n = 60) did not display the characteristics of any group, thus they were not included for this part of the study. All the variables analyzed showed significant differences among the three groups ([Table 1](#pone.0174945.t001){ref-type="table"}). The *post-hoc* analysis between MHNO and MHO, among which the only difference is the presence of obesity, showed differences in the parameters related to body weight: BMI and waist circumference. They also showed differences in SBP, DBP and hs-CRP. The other components of MetS (FPG, TG and HDL-C), FSI and HOMA showed no differences between MHNO and MHO. On the other hand, when we compared MHO with MSO women, similar values in BMI and hs-CRP were observed, but they differ in every component of MetS (waist circumference, FPG, HDL-C, TG, SBP and DBP), as expected considering that both groups are of obese individuals and the difference between them are the presence of MetS. The MSO group also showed significantly higher values in the HOMA and FSI compared to MHO group. The comparison between MHNO and MSO groups showed differences in all the biochemical-clinical parameters analyzed. We also found significant differences in age when comparing the three groups, where the MSO group presented significantly higher age than the other two groups.

10.1371/journal.pone.0174945.t001

###### Characteristics of the population grouped according to the metabolic condition.

![](pone.0174945.t001){#pone.0174945.t001g}

                      Groups         Statistical comparison   Test *post-hoc*                                                                                                                
  ------------------- -------------- ------------------------ ----------------- ---------- -------- --------------- ---------- -------- ---------------- ---------- -------- --------------- ----------
  n                   196            42                       102                                                                                                                            
  Age (years)         42 ± 15        44 ± 15                  51 ± 14           \< 0.001   -1.94    -7.91/4.02      NS         -7.04    -13.47/-0.6      0.027      -8.98    -13.26/-4.69    \< 0.001
  BMI (kg m^-2^)      24.52 ± 2.95   35.33 ± 6.65             36.94 ± 6.17      \< 0.001   -10.82   -12.73/-8.91    \< 0.001   -1.61    -3.67/0.45       NS         -12.43   -13.80/-11.06   \< 0.001
  WC (cm)             86 ± 9         106 ± 10                 112 ± 11          \< 0.001   -19.53   -23.61/-15.45   \< 0.001   -5.97    -10.37/-1.56     0.004      -25.49   -28.43/-22.56   \< 0.001
  FPG (mg dl^-1^)     89 ± 10        90 ± 8                   115 ± 49          \< 0.001   -1.37    -12.86/10.12    NS         -24.55   -36.94/-12.16    \< 0.001   -25.92   -34.17/-17.67   \< 0.001
  FSI (mcU ml-1)      9.95 ± 7.44    12.91 ± 7.99             19.01 ± 15.99     \< 0.001   -2.96    -7.39/1.47      NS         -6.10    -10.87/-1.33     0.007      -9.06    -12.24/-5.88    \< 0.001
  HOMA                2.23 ± 1.79    2.88 ± 1.79              5.53 ± 6.2        \< 0.001   -0.65    -2.17/0.87      NS         -2.65    -4.29/-1.01      \< 0.001   -3.31    -4.40/-2.21     \< 0.001
  HDL-C (mg dl^-1^)   57 ± 13        55 ± 12                  47 ± 12           \< 0.001   2.37     -2.95/7.69      NS         7.97     2.23/13.71       0.003      10.34    6.52/14.16      \< 0.001
  TG (mg dl^-1^)      97 ± 42        92 ± 36                  166 ± 97          \< 0.001   4.59     -21.44/30.62    NS         -73.99   -102.05/-45.93   \< 0.001   -69.40   -88.09/-50.71   \< 0.001
  SBP (mmHg)          111 ± 19       121 ± 20                 137 ± 21          \< 0.001   -9.64    -17.64/-1.65    0.012      -15.45   -24.07/-6.83     \< 0.001   -25.09   -30.83/-19.35   \< 0.001
  DBP (mmHg)          69 ± 12        75 ± 14                  83 ± 11           \< 0.001   -6.11    -10.92/-1.29    0.007      -8.13    -13.31/-2.94     0.001      -14.23   -17.69/-10.77   \< 0.001
  hs-CRP (mg l^-1^)   2.01 ± 2.14    3.18 ± 2.60              3.89 ± 2.57       \< 0.001   -1.17    -2.23/-0.12     0.024      -0.70    -1.85/0.44       NS         -1.88    -2.62/-1.14     \< 0.001

Statistical evaluation: One way-ANOVA and Bonferroni *post-hoc* test.

MHNO: Metabolically Healthy Non-obese individuals; MHO: Metabolically Healthy Obese individuals; MSO: Obese individual with Metabolic Syndrome; M: mean; SD: standard deviation; MD: means difference; 95% CI MD: 95% confidence interval of the means difference; BMI: Body mass index; WC: Waist circumference; FPG: fasting plasma glucose; FSI: Fasting serum insulin; HOMA: Homoeostasis Model Assessment; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; SBP: systolic blood pressure; DBP: diastolic blood pressure; hs-CRP: High-Sensitive C reactive protein; NS: not significant.

The analysis of aTL showed a median value of 12.95 kbp (range: 1.57--72.12 kbp) for the general population. The relationship between aTL and age was evaluated and a significant shortening of aTL with age progression was observed in the general population (p = 0.001; r = -0.12; 95% CI r = -0.20 / -0.05) ([Fig 1](#pone.0174945.g001){ref-type="fig"}).

![Telomere length as a function of age for the general population.\
Statistical evaluation: Linear regression. Mean (─) and standard deviation (-). aTL: Absolute telomere length.](pone.0174945.g001){#pone.0174945.g001}

The median aTL was 14.26 kpb (range: 2.66--72.12 kpb) for MHNO, 14.11 kpb (range: 2.83--60.38 kpb) for MHO, and 12.51 kpb (range: 1.57--64.39 kpb) for MSO individuals. Although the median aTL tend to decrease as the metabolic condition worsens, it did not archive statistical significance (p = 0.054; r = -1.43; 95% CI r = -2.88 / 0.02). The comparison of aTL among groups showed that MSO had significantly shorter aTL than MHNO (p = 0.036; r = -3.13; 95% CI r = -6.06 / -0.21), and MHO (p = 0.033; r = -4.63; 95% CI r = -8.89 / -0.37), but we found no differences in aTL between MHNO and MHO (p = 0.456, r = -1.50; 95% CI r = -5.44 / 2.45) ([Fig 2A](#pone.0174945.g002){ref-type="fig"}), indicating that aTL was influenced by the presence of MetS, but it was not affected by the presence of obesity. All these results were performed with age-squared, tobacco consumption and physical activity corrections. Thus, in order to evaluate the relationship between aTL and the number of MetS components, we regrouped the population according to the number of components of the MetS.

![**Telomere length according to the metabolic condition (A) and according to the number of components of metabolic syndrome (B).** Statistical evaluation: Multiple linear regression and the study of dummy variables. Covariates: age, pack-years smoked and physical activity. aTL: Absolute telomere length; MHNO: Metabolically Healthy Non-obese individuals; MHO: Metabolically Healthy Obese individuals; MSO: Obese individual with Metabolic Syndrome; MetS: Metabolic Syndrome (individual with three or more components).](pone.0174945.g002){#pone.0174945.g002}

From the total of 400 women of the general population, 18.5% (n = 74) had no components of MetS (group 0), 20.0% (n = 80) showed one component (group 1), 21.0% (n = 84) had two components (group 2) and 40.5% (n = 162) showed three or more components (group MetS). All biochemical-clinical characteristics analyzed showed significant differences among the four groups ([Table 2](#pone.0174945.t002){ref-type="table"}). In the *post-hoc* comparison the group with MetS differed from all other groups without MetS (0, 1 and 2) in all variables analyzed.

10.1371/journal.pone.0174945.t002

###### Characteristics of the population grouped according to the Metabolic Syndrome number of components.

![](pone.0174945.t002){#pone.0174945.t002g}

  ------------------- ------------------------------- ---------------------------- --------------- --------------- ---------------- ---------- -------- -------------- ----------
  **A**               **MetS number of components**   **Statistical comparison**                                                                                       
                      **0**                           **1**                        **2**           **MetS**                                                            
                      M ± SD                          M ± SD                       M ± SD          M ± SD          P                                                   
  n                   74                              80                           84              162                                                                 
  Age (years)         35 ± 10                         39 ± 15                      51 ± 14         53 ± 14         \< 0.001                                            
  BMI (kg m^-2^)      24.23 ± 3.06                    26.31 ± 5.34                 28.48 ± 6.86    33.12 ± 7.14    \< 0.001                                            
  WC (cm)             84 ± 10                         89 ± 11                      95 ± 13         105 ± 14        \< 0.001                                            
  FPG (mg dl^-1^)     86 ± 8                          89 ± 8                       92 ± 11         112 ± 44        \< 0.001                                            
  FSI (mcU ml^-1^)    10.14 ± 7.93                    9.11 ± 5.88                  12.07 ± 8.54    16.38 ± 13.96   \< 0.001                                            
  HOMA                2.18 ± 1.81                     2.02 ± 1.34                  2.80 ± 2.08     4.68 ± 5.25     \< 0.001                                            
  HDL-C (mg dl^-1^)   64 ± 11                         52 ± 12                      54 ± 14         47 ± 13         \< 0.001                                            
  TG (mg dl^-1^)      78 ± 28                         89 ± 31                      117 ± 50        170 ± 97        \< 0.001                                            
  SBP (mmHg)          103 ± 12                        113 ± 20                     122 ± 19        135 ± 21        \< 0.001                                            
  DBP (mmHg)          65 ± 8                          70 ± 12                      76 ± 13         81 ± 12         \< 0.001                                            
  hs-CRP (mg l^-1^)   1.70 ± 1.69                     2.43 ± 2.49                  2.43 ± 2.44     3.73 ± 2.48     \< 0.001                                            
  **B**               **Test *post-hoc***                                                                                                                              
                      **0 vs 1**                      **0 vs 2**                   **1 vs 2**                                                                          
                      MD                              95% CI MD                    p               MD              95% CI MD        p          MD       95% CI MD      p
  Age (years)         -4.02                           -9.84/1.81                   NS              -15.43          -21.19/-9.67     \< 0.001   -11.42   -17.06/-5.77   \< 0.001
  BMI (kg m^-2^)      -2.08                           -4.72/0.55                   NS              -4.25           -6.85/-1.64      \< 0.001   -2.17    -4.72/0.38     NS
  WC (cm)             -4.35                           -9.57/0.87                   NS              -10.68          -15.84/-5.52     \< 0.001   -6.33    -11.39/-1.28   0.006
  FPG (mg dl^-1^)     -3.43                           -15.69/8.83                  NS              -6.42           -18.53/5.7       NS         -2.98    -14.86/8.89    NS
  FSI (mcU ml^-1^)    1.03                            -3.56/5.61                   NS              -1.94           -6.47/2.6        NS         -2.96    -7.37/1.45     NS
  HOMA                0.16                            -1.4/1.71                    NS              -0.62           -2.16/0.92       NS         -0.78    -2.27/0.72     NS
  HDL-C (mg dl^-1^)   11.50                           6.16/16.84                   \< 0.001        9.46            4.18/14.74       \< 0.001   -2.04    -7.2/3.11      NS
  TG (mg dl^-1^)      -10.76                          -40.1/18.58                  NS              -38.81          -67.81/-9.8      0.003      -28.05   -56.47/0.37    NS
  SBP (mmHg)          -9.71                           -17.79/-1.63                 0.009           -19.27          -27.25/-11.28    \< 0.001   -9.56    -17.38/-1.73   0.008
  DBP (mmHg)          -5.13                           -10.04/-0.21                 0.036           -10.84          -15.69/-5.98     \< 0.001   -5.71    -10.47/-0.96   0.009
  hs-CRP (mg l^-1^)   -0.73                           -1.78/0.33                   NS              -0.73           -1.77/0.3        NS         0.00     -1.05/1.04     NS
  **C**               **Test *post-hoc***                                                                                                                              
                      **0 vs MetS**                   **1 vs MetS**                **2 vs MetS**                                                                       
                      MD                              95% CI MD                    p               MD              95% CI MD        p          MD       95% CI MD      p
  Age (years)         -17.89                          -22.96/-12.82                \< 0.001        -13.87          -18.81/-8.93     \< 0.001   -2.45    -7.31/2.41     NS
  BMI (kg m^-2^)      -8.90                           -11.19/-6.6                  \< 0.001        -6.82           -9.05/-4.58      \< 0.001   -4.65    -6.84/-2.45    \< 0.001
  WC (cm)             -20.51                          -25.06/-15.97                \< 0.001        -16.16          -20.59/-11.73    \< 0.001   -9.83    -14.18/-5.47   \< 0.001
  FPG (mg dl^-1^)     -25.83                          -36.51/-15.16                \< 0.001        -22.40          -32.8/-12        \< 0.001   -19.42   -29.65/-9.19   \< 0.001
  FSI (mcU ml^-1^)    -6.25                           -10.25/-2.25                 \< 0.001        -7.28           -11.13/-3.42     \< 0.001   -4.31    -8.11/-0.52    0.017
  HOMA                -2.51                           -3.87/-1.15                  \< 0.001        -2.66           -3.98/-1.35      \< 0.001   -1.89    -3.18/-0.6     0.001
  HDL-C (mg dl^-1^)   16.55                           11.90/21.21                  \< 0.001        5.05            0.54/9.56        0.019      7.10     2.65/11.53     \< 0.001
  TG (mg dl^-1^)      -91.59                          -117.14/-66.04               \< 0.001        -80.84          -105.72/-55.95   \< 0.001   -52.79   -77.27/-28.3   \< 0.001
  SBP (mmHg)          -31.64                          -38.66/-24.61                \< 0.001        -21.93          -28.77/-15.08    \< 0.001   -12.37   -19.1/-5.64    \< 0.001
  DBP (mmHg)          -16.50                          -20.77/-12.23                \< 0.001        -11.37          -15.53/-7.21     \< 0.001   -5.66    -9.75/-1.57    0.002
  hs-CRP (mg l^-1^)   -2.03                           -2.94/-1.12                  \< 0.001        -1.30           -2.22/-0.38      0.001      -1.30    -2.19/-0.41    0.001
  ------------------- ------------------------------- ---------------------------- --------------- --------------- ---------------- ---------- -------- -------------- ----------

Statistical evaluation: One way-ANOVA (A) and Bonferroni *post-hoc* test (B-C).

MetS: Metabolic Syndrome; M: mean; SD: standard deviation; MD: means difference; 95% CI MD: 95% confidence interval of the means difference; BMI: Body mass index; WC: Waist circumference; FPG: fasting plasma glucose; FSI: Fasting serum insulin; HOMA: Homoeostasis Model Assessment; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; SBP: systolic blood pressure; DBP: diastolic blood pressure; hs-CRP: High-Sensitive C reactive protein; NS: not significant.

The median aTL was 16.35 kpb (range: 2.86--64.99 kpb) for individuals with no components of MetS, 13.24 kpb (range: 2.66--72.12 kpb) for individuals with one component, 12.75 kpb (range: 2.66--51.57 kpb) for individuals with two components, and 11.91 kpb (range: 1.57--64.39 kpb) for individuals with MetS. It can be seen that the median aTL is shorter with the presence of MetS abnormalities, and that it becomes shorter with the increase in the number of components of the MetS. In addition, we observed statistically significant association between aTL and the number of components of MetS with age-square, tobacco consumption and physical activity corrections (p \< 0.001; r = -2.06; 95% CI r = -3.13 / -0.99) ([Fig 2B](#pone.0174945.g002){ref-type="fig"}). The comparison between groups showed that individual with no components of MetS (group 0) had aTL significantly longer than the other groups (0 vs 1: p = 0.007, r = -4.87, 95% CI r = -8.42 / -1.31; 0 vs 2: p = 0.006, r = -5.15, 95% CI r = -8.85 / -1.46; 0 vs MetS: p \< 0.001, r = -7.06, 95% CI r = -10.44 / -3.69), with no differences between groups 1, 2 and MetS (1 vs MetS: p = 0.173, r = -2.19, 95% CI r = -5.35 / 0.97; 2 vs MetS: p = 0.208, r = -1.91, 95% CI r = -4.88 / 1.06; 1 vs 2: p = 0.874, r = -0.29, 95% CI r = -3.82 / 3.25), reinforcing the idea that the presence of at least one of the MetS components is associated with a shorter aTL.

Discussion {#sec011}
==========

This is the first description about aTL in a population of MHO patients compared to MSO and MHNO individuals. To our knowledge, this is the first report showing that MHO group had no differences in aTL with respect to the MHNO group, but it shows significant differences with respect to the MSO group.

MHO group would be defined as a subgroup of obese patients with an intermediate phenotype between MHNO and MSO individuals. In this way, when we compared MHO and MSO groups we found that both had similar BMI, but they differ in every component of MetS. The difference in waist circumference demonstrates the importance of central obesity in the development of MetS. Actually, it is accepted that visceral and ectopic fat content has been associated with a decrease in insulin sensitivity, which could play an important role in the development of metabolic complications and increase risk of CVD. In that sense, we observed that although MHO individuals have large quantities of fat mass, they might present remarkably normal to high levels of insulin sensitivity. This could be due to MHO individuals which show 49% less visceral adipose tissue (as measured from computed tomography) than at risk subjects with the MetS \[[@pone.0174945.ref028]\]. On the other hand, when we compared MHNO and MHO they showed differences in BMI, waist circumference and blood pressure, but not in the other components of MetS. We could see that MHO had similar CRP than MSO, as recently found in Brazilian population \[[@pone.0174945.ref029]\]. Also, when we evaluated the insulin resistance, we found that MHO had significantly lower HOMA index compared to MSO patients, and that MHO and MHNO did not differ with respect to insulin sensibility. Similar results have been published in metabolically healthy peripherally obese \[[@pone.0174945.ref030]\].

When MHO was followed up during longitudinal studies in order to investigate the cardiovascular risk and mortality, results showed that MHO group is a clinical entity in between healthy non-obese individuals and MetS individuals. A 7-years prospective study found that MHO subjects did not have an increased risk for CVD or all-cause mortality compared with healthy non-obese individuals \[[@pone.0174945.ref031]\]. However, another study with a follow-up period of 7.4 years revealed that obese participants without MetS had higher risk of major cardiovascular events compared with metabolically healthy non-obese subjects but less than unhealthy metabolic non-obese individuals \[[@pone.0174945.ref032]\]. A recent meta-analysis that evaluated participants for all-cause mortality and/or CVD showed an increased risk for CVD in MHO individuals compared to metabolically healthy normal weight individuals (OR \[[Odds ratio](http://escuela.med.puc.cl/recursos/recepidem/indepi5.htm)\] = 1.24, 95% CI = 1.02--1.55), but fewer than obese unhealthy individuals (OR = 2.65; 95% CI = 2.18--3.12) \[[@pone.0174945.ref033]\]. Furthermore, the patients with coronary artery disease who presented MetS had shorter TL than patients without MetS \[[@pone.0174945.ref034]\].

Our molecular analysis showed that aTL in MHO group is similar to that observed in MHNO and larger than in MSO individuals, supporting the finding that those patients have a better metabolic behavior than MetS individuals.

Another finding of our work was that the aTL is dependent upon the presence of metabolic abnormalities. Thus, we could associate shorter aTL with the raise in the number of MetS components, supporting a relationship between telomere shortening and the metabolic severity. In agreement with our results, a recent report \[[@pone.0174945.ref035]\] found that shorter TL was related with a higher number of MetS abnormalities representing a more severe metabolic profile. Although this association, found at baseline of the study, was reduced over two to six years follow up, shorter baseline TL was still significantly associated with unfavorable scores of most MetS components. In addition, Njajou et al \[[@pone.0174945.ref036]\] published similar findings, where a seven years follow up was associated with smaller increases in BMI and body fat in those individuals who presented longer TL. Rehkopf et al \[[@pone.0174945.ref037]\] in a large nationally representative U.S. sample did not find an association between MetS and shorter TL. They did not report the prevalence of MetS in their population and not stratify the individuals in accordance to the variables of MetS, as we performed in our study. Although we found shorter aTL in MSO and an association with the number of MetS components, like Rehkopf we could not associate MetS with shorter aTL. In this sense, we had not found association between TL and the individual components of MetS (data not shown). Anyway, we must consider genetics, ethnics, demographics, feeding and behaviors differences between both populations that may interfere the relationship between TL and MetS.

Several issues may influence the TL; some of them are not modifiable such as age, inheritance, gender and ethnicity, among the most important ones. On the other hand, there are modifiable clinical variables that may determine the TL, such as high FPG, increase BMI and waist circumference, high TG, reduced HDL-C, smoking, physical activity, and diet. In this respect, different studies showed the relationship between TL and metabolic abnormalities \[[@pone.0174945.ref038]--[@pone.0174945.ref040]\]. In our study, we could associate the number of metabolic alterations with aTL. In this respect, molecular mechanism such as inflammation and oxidative damage could lead to short telomeres as a consequence of a worsened metabolic state as we demonstrated in this work \[[@pone.0174945.ref041]\]. Interestingly, the increasing in abdominal adiposity was found to be accompanied by shorter TL, in the same way we found that MHO had a waist circumference lowest than MSO \[[@pone.0174945.ref042]\]. In this regards, recently an Editorial has been published about MHO which includes definition, metabolic outcomes, molecular genetics findings and therapeutic interventions \[[@pone.0174945.ref043]\]. This paper claims the need about longitudinal trials in individuals who are MHO at baseline and determine the development of the typical metabolic complications of obesity and the molecular genetics mechanisms contributing toward its development. Beyond whether MHO is or not a clinical entity, we could associate the shorter aTL to the increased presence of metabolic disorders, emphasizing the importance of its clinical management to prevent cardiovascular disease.

Martin-Ruiz et al \[[@pone.0174945.ref044]\] published that the variation of the TL and the amount of methodological differences between laboratories is large and it has been demonstrated a huge inter-laboratory variation even for relative TL following internal normalization. In general, it must be considered that the same reference range for TL cannot be applied by all laboratories. So, TL measurement of an individual or a group of individuals could only be useful as a risk indicator if reference values were measured by the same laboratory using the same protocols.

In conclusion, we are showing for the first time that aTL in MHO women is similar to that in MHNO women, and longer than that observed in MSO women, suggesting its importance in the interpretation of physiopathology and treatment of this subtype of obesity \[[@pone.0174945.ref045]\]. Our work has some limitations: (i) it was carried out only in women, (ii) we studied the aLT average of all white blood cells in peripheral circulation without controlling for cell type, (iii) oxidative stress molecular markers were not determined. Nevertheless, our report indicates that: (i) some metabolic conditions such as MHO, is not associated with shorter aTL; and (ii) shorter aTL is related to MetS and with the increased number of metabolic abnormalities, representing a more severe metabolic profile and finally that the shortening of the aTL throughout life is less pronounced in individuals with normal weight and without metabolic abnormalities. Although some findings are consistent with a role for TL in the etiology of CVD and MetS, is unclear the exact relationship between them \[[@pone.0174945.ref046]\]. We thought that the TL shortens as a consequence of multiple types of biochemical stressors and may represent an index of several known risk factors. In this way, our study may contribute to this matter.
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